Cost of HAART in italy: Multicentric evaluation and determinants from a large HIV outpatient cohort

ClinicoEconomics and Outcomes Research

Volumn 7, Issue , 2014, Pages 27-35

  Tontodonati, Monica ^a,b   Cenderello, Giovanni ^c   Celesia, Benedetto Maurizio ^d   Trezzi, Michele ^e   Ursini, Tamara ^b   Costantini, Andrea ^f   Marra, Domenico ^c   Polilli, Ennio ^a   Catalani, Corrado ^e   Butini, Luca ^f   Sozio, Federica ^a   Mazzotta, Elena ^b   Sciacca, Antonina ^a   Rizzardini, Giuliano ^g   Manzoli, Lamberto ^b   Cozzi Lepri, Alessandro ^h   Parruti, Giustino ^a  

^a Pescara General Hospital   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c GALLIERA HOSPITAL   (Italy)

^d ARNAS Garibaldi   (Italy)

^e Pistoia General Hospital   (Italy)

^f Ancona Hospital   (Italy)

^g UNIVERSITY OF MILAN   (Italy)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Costs; Current CD4 count; Highly active antiretroviral treatment; Human immunodeficiency virus; Treatment failures; Viremia

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DRUG COST; DRUG TREATMENT FAILURE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ITALY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTPATIENT; PREDICTION; PREVALENCE; RETROSPECTIVE STUDY; SOCIAL DETERMINANTS OF HEALTH; VIREMIA;

EID: 84919790573     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S69183     Document Type: Article

References (25)

1. Magoni M, Scarcella C, Vassallo F, et al. The evolving burden of HIV infection compared with other chronic diseases in northern Italy. HIV Med. 2011;12:129-137.
2. Levy AR, James D, Johnston KM, et al. The direct costs of HIV/AIDS care. Lancet Infect Dis. 2006;6:171-177.
3. Sullivan R, Peppercorn J, Sikora K, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol. 2011;12:933-980.
4. Sloan CE, Champenois K, Choisy P, et al. Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults. AIDS. 2012;26:45-56.
5. Krentz HB, Auld MC, Gill MJ; for the HIV Economic Study Group. The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001. CMAJ. 2003;169:106-110.
6. Merito M, Bonaccorsi A, Pammolli F, et al. Economic evaluation of HIV treatments: the ICONA cohort study. Health Policy. 2005;74: 304-313.
7. Krentz HB, Gill J. Despite CD4 cell count rebound the higher initial costs of medical care for HIV-infected patients persist 5 years after presentation with CD4 cell counts less than 350 microL. AIDS. 2010;24: 2750-2753.
8. Rizzardini G, Restelli U, Bonfanti P, et al. The cost of HIV disease in Northern Italy: the payer’s perspective. J Acquir Immune Defic Syndr. 2011;57:211-217.
9. Cohen MS, Chen YQ, McCauley M, et al; HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493-505.
10. Center for Disease Control and Prevention. Preexposure prophylaxis for the prevention of HIV infection on the United States 2014. Available from: http://www.cdc.gov/hiv/pdf/PrEPguidelines2014.pdf. Accessed June 8, 2014.
11. Foreman C, Gazzard B, Johnson M, Sharott P, Collins S. Maintaining cost-effective access to antiretroviral drug therapy through a collaborative approach to drug procurement, consensus treatment guidelines and regular audit: the experience of London HIV commissioners and providers. Sex Transm Infect. 2012;88:112-115.
12. Gazzard B, Moecklinghoff C, Hill A. New strategies for lowering the costs of antiretroviral treatment and care for people with HIV/AIDS in the United Kingdom. Clinicoecon Outcomes Res. 2012;4:193-200.
13. Helleberg M, Engsig FN, Kronborg G, et al. Retention in a public healthcare system with free access to treatment: a Danish nationwide HIV cohort study. AIDS. 2012;26:741-748.
14. Hall HI, Halverson J, Wilson DP, et al. Late diagnosis and entry to care after diagnosis of human immunodeficiency virus infection: a country comparison. PLoS One. 2013;8:e77763.
15. Parruti G, Vadini F, Sozio F, et al. Psychological factors, including alexithymia, in the prediction of cardiovascular risk in HIV infected patients: results of a cohort study. PLoS One. 2013;8:e54555.
16. Cozzi-Lepri A, Prosperi MC, Kjær J, et al. Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score. PLoS ONE. 2011;6:e25665.
17. Tibshirani R. Regression shrinkage and selection via the Lasso. J R Stat Soc Series B Stat Methodol. 1996;58:267-288.
18. Efron B, Hastie T, Johnstone I, Tibshirani R. Least angle regression. Ann Stat. 2004;32:407-499.
19. Tontodonati M, Sozio F, Vadini F, et al. A multifactorial risk score to evaluate baseline and antiretroviral-related toxicities relative to the costs of current antiretroviral regimens in a cohort of HIV-infected patients. Oral communication OC40 presented at the Ninth Italian Conference on AIDS and Retroviruses, June 10-12, 2012, Naples, Italy.
20. Rizzardini G, Restelli U, Bonfanti P, et al, Cost of human immunodeficiency virus infection in Italy, 2007-2009: effective and expensive, are the new drugs worthwhile? Clinicoecon Outcome Res. 2012;4: 245-252.
21. Oliva-Moreno J, López-Bastida J, Serrano-Aguilar P, Perestelo-Pérez L. Determinants of health care costs of HIV-positive patients in the Canary Island, Spain. Eur J Health Econ. 2010,11:405-412.
22. Mostardt S, Hanhoff N, Wasem J, et al. Cost of HIV and determinants of health care costs in HIV-positive patients in Germany: results of the DAGNA K3A Study. Eur J Health Econ. 2013;14:799-808.
23. Fong R, Cheng AC, Vujovic O, Hoy JF. Factors associated with virological failure in a cohort of combination antiretroviral therapy-treated patients managed at a tertiary referral centre. Sex Health. 2013;10: 442-447.
24. Laprise C, de Pokomandy A, Baril JG, Dufresne S, Trottier H. Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation. Clin Infect Dis. 2013;57: 1489-1496.
25. Krentz HB, Auld MC, Gill MJ. The high cost of medical care for patients who present late (CD4,200 cells/microL) with HIV infection. HIV Med. 2004;5:93-98.